Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 6, 2009, Pages 2012-2017

  Tan, Yossan Var ^a   Abad, Catalina ^a   Lopez, Robert ^a   Dong, Hongmei ^a   Liu, Shen ^a   Lee, Alice ^a   Gomariz, Rosa P ^b   Leceta, Javier ^b   Waschek, James A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c NRB 345 ^*  (United States)

Author keywords

Autoimmunity; Inflammation; Knock out; Multiple sclerosis; Regulatory T cell

Indexed keywords

ACEBUTOLOL; CD4 ANTIGEN; GAMMA INTERFERON; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 12P35; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23P19; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION; LYMPH NODES; LYMPHOCYTE COUNT; MICE; MICE, KNOCKOUT; MYELIN-ASSOCIATED GLYCOPROTEIN; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, CCR; SPINAL CORD; T-LYMPHOCYTES, REGULATORY; VASOACTIVE INTESTINAL PEPTIDE;

MURINAE; MUS;

EID: 60549089799     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812257106     Document Type: Article

References (37)

1. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747.
2. Steinman L, Zamvil SS (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60(1):12-21.
3. Miyata A, et al. (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164(1):567-574.
4. Lutz EM, et al. (2006) Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Mol Cell Neurosci 31(2):193-209.
5. Vaudry D, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52(2):269-324.
6. Botia B, et al. (2007) Neurotrophic effects of PACAP in the cerebellar cortex. Peptides 28(9):1746-1752.
7. Somogyvari-Vigh A, Reglodi D (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 10(23):2861-2889.
8. Waschek JA (2002) Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci 24(1):14 -23.
9. Watanabe J, et al. (2007) Localization, characterization and function of pituitary adenylate cyclase-activating polypeptide during brain development. Peptides 28(9):1713-1719.
10. Lelievre V, et al. (2008) Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. Dev Biol 313(1):359-370.
11. Armstrong BD, et al. (2008) Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience 151(1):63-73.
12. Lee M, et al. (2001) Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors. J Neurosci 21(11):3849-3859.
13. Waschek JA, et al. (1998) Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. Proc Natl Acad Sci USA 95(16):9602-9607.
14. Delgado M, Pozo D, Ganea D (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56(2):249-290.
15. Gonzalez-Rey E, Delgado M (2007) Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 13(6):241-251.
16. Abad C, et al. (2002) Pituitary adenylate-cyclase-activating polypeptide expression in the immune system. Neuroimmunomodulation 10(3):177-186.
17. Leceta J, Martinez C, Delgado M, Garrido E, Gomariz RP (1996) Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv Neuroimmunol 6(1):29-36.
18. Martinez C, et al. (1999) Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 93(1-2):126-138.
19. Gonzalez-Rey E, et al. (2006) Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168(4):1179-1188.
20. Kato H, et al. (2004) Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 10(6):651-659.
21. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7(5):563-568.
22. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M (2001) Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol 167(6):3182-3189.
23. Abad C, et al. (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124(4):961-971.
24. Azuma YT, et al. (2008) PACAP provides colonic protection against dextran sodium sulfate induced colitis. J Cell Physiol 216(1):111-119.
25. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M (2006) Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 36(2):318-326.
26. Delgado M, Gonzalez-Rey E, Ganea D (2005) The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 175(11):7311-7324.
27. Colwell CS, et al. (2004) Selective deficits in the circadian light response in mice lacking PACAP. Am J Physiol Regul Integr Comp Physiol 287(5):R1194-1201.
28. Korn T, Anderson AC, Bettelli E, Oukka M (2007) The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J Neuroimmunol 191(1-2):51-60.
29. Tang Q, Bluestone JA (2006) Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 212:217-237.
30. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146.
31. Zhang Y, Danielsen N, Sundler F, Mulder H (1998) Pituitary adenylate cyclase-activating peptide is upregulated in sensory neurons by inflammation. Neuroreport 9(12):2833-2836.
32. Armstrong BD, et al. (2004) Induction of neuropeptide gene expression and blockade of retrograde transport in facial motor neurons following local peripheral nerve inflammation in severe combined immunodeficiency and BALB/C mice. Neuroscience 129(1):93-99.
33. Armstrong BD, et al. (2003) Lymphocyte regulation of neuropeptide gene expression after neuronal injury. J Neurosci Res 74(2):240-247.
34. Zhou X, et al. (1999) Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus. J Neurosci Res 57(6):953-961.
35. Marie JC, Letterio JJ, Gavin M, Rudensky AY (2005) TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201(7):1061-1067.
36. Delgado M (2003) VIP: a very important peptide in T helper differentiation. Trends Immunol 24(5):221-224.
37. Margolis G, Pickett JP (1956) New applications of the Luxol fast blue myelin stain. Lab Invest 5(6):459-474.